Clinical Trial Update: Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib in combination with pembrolizumab for PD-L1–positive, treatment-naïve non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: NSCLC | Phase 2 | Status: UNKNOWN